NEW YORK, Dec. 4, 2023 /PRNewswire/ — The rheumatoid arthritis drugs market is expected to grow by USD 16.04 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 7.5% during the forecast period, according to Technavio Research. The market is segmented by drug class (disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, and corticosteroids), type (biologics and small molecules), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America accounts for 39% of the growth of the global market during the forecast period. North America is a prominent market with the existence of leading market players for RA drugs, such as AbbVie, Amgen, and Johnson and Johnson. The initiatives by organizations, such as the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the North American College of Rheumatology are other factors that contribute to the significant market share of North America. Hence, such factor drives the market growth in North America.
Technavio has announced its latest market research report titled Global Rheumatoid Arthritis Drugs Market 2024-2028
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report
Company Profile:
AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA
AbbVie Inc: The company offers rheumatoid arthritis drugs namely Rinvoq that demonstrate both strong clinical performance and benefits to patients
• To gain access to more company profiles available with Technavio, buy the report!
Rheumatoid Arthritis Drugs Market: Segmentation Analysis
The market share growth by the disease-modifying anti-rheumatic drugs segment is significant during the forecast period. Disease-modifying anti-rheumatic drugs (DMARDs) mainly comprise methotrexate, sulfasalazine, leflunomide, etanercept, and infliximab. In addition, Nonsteroidal anti-inflammatory drugs (NSAIDs) and DMARDs both relieve the symptoms of active rheumatoid arthritis, but only DMARDs have been proven to affect the course of the illness and improve radiological results. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report
“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio
Rheumatoid Arthritis Drugs Market: Driver & Trend:
Rising cases of RA and the focus on an increasing number of rheumatologists drive the market growth. The high number of cases of RA is expected to fuel the growth of the rheumatoid arthritis drugs market globally. Moreover, there are various associations that include rheumatology specialists, including the Indian Rheumatology Association (IRA). Furthermore, IRA aims to fight against arthritis by means of regular scientific workshops, conferences, symposia, and special interest groups. Such associations are increasingly emerging across the world which drives the market growth.
Availability of improved diagnostic modalities
Need for affordable biologics for RA
Trend –
The use of biologics/biosimilars for the treatment of RA is the primary trend driving the market growth. The biologics have targeted mechanisms of action and serve as profitable molecules for the successful treatment of RA. In addition, biosimilars, which are replicas of biologics, are available at low prices and will likely invade the rheumatoid arthritis drugs market. Hence, such factors are driving the market growth.
Strategic alliances among market vendors are a key trend in the tyrosine kinase inhibitors market. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports:
The insomnia therapeutics market size is estimated to grow by USD 1,002.93 million at a CAGR of 5.49% between 2022 and 2027.
The gonorrhea therapeutics market size is estimated to grow by USD 506.68 million at a CAGR of 5.47% between 2022 and 2027.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Drug Class
Market Segmentation by Type
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
